Item 9 Labs (INLB) Stock Price, News & Analysis
Company Description
Item 9 Labs (OTC Link: INLB) is classified in the drug manufacturers - specialty & generic industry within the Healthcare sector and carries a market capitalization of $10.2K.
For FY2022, Item 9 Labs reported revenue of $21.8M with net income of -$31.2M and diluted earnings per share of -$0.33. The company operates at a net profit margin of -143.3%.
This page collects what Stock Titan holds for INLB, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Item 9 Labs (INLB) stock last closed at $0.0000. At a market capitalization of $10.2K, INLB is classified as a micro-cap stock with approximately 102.4M shares outstanding.
Latest News
Item 9 Labs has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 7 with negative movement. Key topics include conferences. View all INLB news →
SEC Filings
Financial Highlights
Item 9 Labs generated $21.8M in revenue in FY2022, retaining a 33.6% gross margin, operating income reached -$23.1M (-106.0% operating margin), and net income was -$31.2M, reflecting a -143.3% net profit margin. Diluted earnings per share stood at -$0.33. The company generated -$2.3M in operating cash flow. With a current ratio of 0.09, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
INLB Company Profile & Sector Positioning
Item 9 Labs (INLB) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing INLB often look at related companies in the same sector, including Halo Collective Inc (HCANF), Avivagen (VIVXF), Bloomios Inc (BLMS), Veritas Farms (VFRM), and Onassis Holdings Corp (ONSS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate INLB's relative position within its industry.